Tarsus Pharmaceuticals (TARS) Net Margin (2021 - 2026)

Tarsus Pharmaceuticals' Net Margin history runs 6 years deep, the most recent figure standing at 4.28% for Q1 2026.

• On a quarterly basis, Net Margin rose 2769.0% year-over-year to 4.28% in Q1 2026; TTM through Mar 2026 was 27.95%, a 1611.0% increase from a year earlier, with the FY2025 full-year figure at 14.72%, up 4845.0% from the prior year.
• Net Margin slipped to 4.28% in Q1 2026 per TARS's latest filing, from 4.11% in the prior quarter.
• Across five years, Net Margin topped out at 4.11% in Q4 2025 and bottomed at 3680.52% in Q1 2022.
• The 5-year median for Net Margin is 76.64% (2024), against an average of 509.89%.
• Biggest YoY gain for Net Margin was 415951 bps in 2022; the steepest drop was 371133 bps in 2022.
• Year by year, Net Margin stood at 131.02% in 2022, then plunged by 148 bps to 324.72% in 2023, then soared by 89 bps to 34.84% in 2024, then surged by 88 bps to 4.11% in 2025, then slipped by 4 bps to 4.28% in 2026.
• Per Business Quant, the three latest TARS Net Margin figures stand at 4.28% (Q1 2026), 4.11% (Q4 2025), and 10.69% (Q3 2025).